Literature DB >> 10859581

Low molecular weight heparin in the treatment of acute deep vein thrombosis and pulmonary embolism: A paradigm change in care.

G J Merli1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10859581     DOI： 10.1023/a:1018756302725

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  10 in total

1.  A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.

Authors:  G Simonneau; H Sors; B Charbonnier; Y Page; J P Laaban; R Azarian; M Laurent; J L Hirsch; E Ferrari; J L Bosson; D Mottier; B Beau
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

2.  A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.

Authors:  F A Anderson; H B Wheeler; R J Goldberg; D W Hosmer; N A Patwardhan; B Jovanovic; A Forcier; J E Dalen
Journal:  Arch Intern Med       Date:  1991-05

3.  Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.

Authors:  H R Büller; M Gent; A S Gallus; J Ginsberg; M H Prins; R Baildon
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

4.  Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin.

Authors:  H Partsch; B Kechavarz; A Mostbeck; H Köhn; C Lipp
Journal:  J Vasc Surg       Date:  1996-11       Impact factor: 4.268

5.  Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.

Authors:  R D Hull; G E Raskob; G F Pineo; D Green; A A Trowbridge; C G Elliott; R G Lerner; J Hall; T Sparling; H R Brettell
Journal:  N Engl J Med       Date:  1992-04-09       Impact factor: 91.245

6.  Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.

Authors:  G Simonneau; B Charbonnier; H Decousus; B Planchon; J Ninet; P Sie; M Silsiguen; S Combe
Journal:  Arch Intern Med       Date:  1993-07-12

7.  A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.

Authors:  M Levine; M Gent; J Hirsh; J Leclerc; D Anderson; J Weitz; J Ginsberg; A G Turpie; C Demers; M Kovacs
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

8.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

9.  Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.

Authors:  P Lindmarker; M Holmström; S Granqvist; H Johnsson; D Lockner
Journal:  Thromb Haemost       Date:  1994-08       Impact factor: 5.249

10.  Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.

Authors:  H W de Valk; J D Banga; J W Wester; C B Brouwer; M W van Hessen; O J Meuwissen; H C Hart; J J Sixma; H K Nieuwenhuis
Journal:  Ann Intern Med       Date:  1995-07-01       Impact factor: 25.391
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.